Skip to main content
logo
Medtronic plc (MDT)
NYSE: MDT · Real-Time Price · USD
96.76
-2.24 (-2.26%)
At close: Jan 16, 2026, 4:00 PM EST
96.85
+0.09 (0.09%)
After-hours: Jan 16, 2026, 7:58 PM EST

Revenue

Millions USD. Fiscal year is May - Apr.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 20222012 - 2021
Period Ending
Oct '25 Apr '25 Apr '24 Apr '23 Apr '22 2012 - 2021
Cardiac Rhythm & Heart Failure Revenue
6.82B6.39B
Log In
Log In
Log In
Upgrade
Structural Heart & Aortic Revenue
3.70B3.55B
Log In
Log In
Log In
Upgrade
Coronary & Peripheral Vascular Revenue
2.58B2.54B
Log In
Log In
Log In
Upgrade
Cardiovascular Revenue
13.09B12.48B
Log In
Log In
Log In
Upgrade
Cranial & Spinal Technologies Revenue
5.10B4.97B
Log In
Log In
Log In
Upgrade
Specialty Therapies Revenue
2.94B2.94B
Log In
Log In
Log In
Upgrade
Neuromodulation Revenue
2.02B1.93B
Log In
Log In
Log In
Upgrade
Neuroscience Revenue
10.06B9.85B
Log In
Log In
Log In
Upgrade
Surgical & Endoscopy Revenue
6.60B6.50B
Log In
Log In
Log In
Upgrade
Acute Care & Monitoring Revenue
1.94B1.91B
Log In
Log In
Log In
Upgrade
Medical Surgical Revenue
8.54B8.41B
Log In
Log In
Log In
Upgrade
Diabetes Revenue
2.90B2.76B
Log In
Log In
Log In
Upgrade
Other Segment Revenue
170.00M137.00M
Log In
Log In
Log In
Upgrade
Revenue (Other)
--89.00M
Log In
Log In
Log In
Upgrade
Revenue (Total)
34.76B33.54B
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions USD. Fiscal year is May - Apr.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 20222012 - 2021
Period Ending
Oct '25 Apr '25 Apr '24 Apr '23 Apr '22 2012 - 2021
U.S. Revenue
17.52B17.17B
Log In
Log In
Log In
Upgrade
Non-U.S. Developed Markets Revenue
-10.20B
Log In
Log In
Log In
Upgrade
Emerging Markets Revenue
-6.20B
Log In
Log In
Log In
Upgrade
Total International Revenue
17.23B16.37B
Log In
Log In
Log In
Upgrade
Revenue (Other)
-1.00M
Log In
Log In
Log In
Upgrade
Revenue (Total)
34.76B33.54B
Log In
Log In
Log In
Upgrade

EBIT

Millions USD. Fiscal year is May - Apr.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 20222012 - 2021
Period Ending
Oct '25 Apr '25 Apr '24 Apr '23 Apr '22 2012 - 2021
Cardiovascular Operating Profit
4.22B4.80B
Log In
Log In
Log In
Upgrade
Neuroscience Operating Profit
3.64B4.18B
Log In
Log In
Log In
Upgrade
Medical Surgical Operating Profit
2.60B3.04B
Log In
Log In
Log In
Upgrade
Diabetes Operating Profit
352.00M491.00M
Log In
Log In
Log In
Upgrade
Operating Income (Other)
-4.60B-6.56B
Log In
Log In
Log In
Upgrade
Operating Income (Total)
6.21B5.96B
Log In
Log In
Log In
Upgrade

Key Performance Indicators

Millions USD. Fiscal year is May - Apr.
Fiscal Year
FY 2025FY 2024FY 2023FY 20222012 - 2021
Period Ending
Apr '25 Apr '24 Apr '23 Apr '22 2012 - 2021
Cardiovascular Organic Revenue Growth
6.30%
Log In
Log In
Log In
Upgrade
Neuroscience Organic Revenue Growth
5.20%
Log In
Log In
Log In
Upgrade
Medical Surgical Organic Revenue Growth
0.80%
Log In
Log In
Log In
Upgrade
Diabetes Organic Revenue Growth
11.50%
Log In
Log In
Log In
Upgrade
Total Organic Revenue Growth
4.90%
Log In
Log In
Log In
Upgrade
Updated Nov 18, 2025. Data Source: Fiscal.ai.